Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $19.00 Consensus Price Target from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $19.00.

Several research firms have recently issued reports on FULC. The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. HC Wainwright upped their price target on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Monday, December 8th. Stifel Nicolaus set a $25.00 price objective on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada boosted their target price on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC opened at $7.44 on Tuesday. The stock’s fifty day moving average is $9.76 and its 200 day moving average is $9.62. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $15.74. The firm has a market capitalization of $495.50 million, a PE ratio of -6.31 and a beta of 3.23.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). Equities analysts forecast that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Insider Activity

In related news, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the sale, the director directly owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of FULC. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth $30,000. Meeder Asset Management Inc. bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $39,000. Quarry LP purchased a new position in Fulcrum Therapeutics in the 3rd quarter worth about $35,000. Persistent Asset Partners Ltd purchased a new position in Fulcrum Therapeutics in the 4th quarter worth about $75,000. Finally, Farther Finance Advisors LLC lifted its holdings in Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.